Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
m6A RNA methylation regulators contribute to malignant progression and have clinical prognostic impact in gliomas
- Rui-Chao Chai, Fan Wu, +7 authors Chunsheng Kang
- Biology, Medicine
- Aging
- 27 February 2019
N6-methyladenosine (m6A) RNA methylation, associated with cancer initiation and progression, is dynamically regulated by the m6A RNA methylation regulators (“writers”, “erasers” and “readers”). Here,… Expand
A novel cell cycle-associated lncRNA, HOXA11-AS, is transcribed from the 5-prime end of the HOXA transcript and is a biomarker of progression in glioma.
- Qi-xue Wang, J. Zhang, +6 authors L. Han
- Biology, Medicine
- Cancer letters
- 10 April 2016
The comprehensive lncRNA expression signature in glioma has not yet been fully elucidated. We performed a high-throughput microarray to detect the ncRNA expression profiles of 220 human glioma… Expand
SNORD47, a box C/D snoRNA, suppresses tumorigenesis in glioblastoma
SNORD47 is a member of the C/D box small nucleolar RNAs, which have been implicated in cancer development. We intended to investigate the therapeutic potential of SNORD47 in glioma. We found that the… Expand
Long non-coding RNA HOTAIR mediates the switching of histone H3 lysine 27 acetylation to methylation to promote epithelial-to-mesenchymal transition in gastric cancer
- Y. Song, R. Wang, +4 authors Q. Zhang
- Biology, Medicine
- International journal of oncology
- 5 November 2018
HOX transcript antisense intergenic RNA (HOTAIR), a well-known long non-coding RNA, plays an important role in the regulation of epithelial-to-mesenchymal transition (EMT). In this study, we propose… Expand
Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy
- Q. Zhan, Kaikai Yi, +10 authors Chunsheng Kang
- Chemistry, Medicine
- Theranostics
- 22 June 2020
Rationale: Developing an effective nanoplatform to realize 'multi-in-one' is essential to broaden the therapeutic potential of combination therapy. Exosomes are ideal candidates since their intrinsic… Expand
EGFR/EGFRvIII remodels the cytoskeleton via epigenetic silencing of AJAP1 in glioma cells.
- Chao Yang, Y. Li, +10 authors Chunsheng Kang
- Biology, Medicine
- Cancer letters
- 10 September 2017
EGFR amplification and mutations are the most common oncogenic events in GBM. EGFR overexpression correlates with GBM invasion, but the underlying mechanisms are poorly understood. In a previous… Expand
AC1MMYR2 impairs high dose paclitaxel-induced tumor metastasis by targeting miR-21/CDK5 axis.
- Y. Ren, X. Zhou, +10 authors Chunsheng Kang
- Biology, Medicine
- Cancer letters
- 1 July 2015
Paclitaxel (taxol) is a widely used chemo-drug for many solid tumors, while continual taxol treatment is revealed to stimulate tumor dissemination. We previously found that a small molecule inhibitor… Expand
Targeted design and identification of AC1NOD4Q to block activity of HOTAIR by abrogating the scaffold interaction with EZH2
- Y. Ren, Yun-fei Wang, +4 authors Chunsheng Kang
- Biology, Medicine
- Clinical Epigenetics
- 14 February 2019
BackgroundNearly 25% of long intergenic non-coding RNAs (lincRNAs) recruit chromatin-modifying proteins (e.g., EZH2) to silence target genes. HOX antisense intergenic RNA (HOTAIR) is deregulated in… Expand
Reprogramming carcinoma associated fibroblasts by AC1MMYR2 impedes tumor metastasis and improves chemotherapy efficacy.
- Y. Ren, X. Zhou, +14 authors Chunsheng Kang
- Medicine
- Cancer letters
- 28 April 2016
Carcinoma associated fibroblasts (CAFs) produce a nutrient-rich microenvironment to fuel tumor progression and metastasis. Reactive oxygen species (ROS) levels and the inflammation pathway co-operate… Expand
Dual-Locking Nanoparticles Disrupt the PD-1/PD-L1 Pathway for Efficient Cancer Immunotherapy.
- Z. Zhang, Qi-xue Wang, +11 authors Yifeng Liu
- Materials Science, Medicine
- Advanced materials
- 11 November 2019
The clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) enzyme, Cas13a, holds great promise in cancer treatment due to its potential for selective destruction of… Expand